Barclays’s TriSalus Life Sciences TLSI Stock Holding History

Barclays’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$74.3K	Buy	17,243 +8,596	+99%	+$40.7K	﹤0.01%	4433
2026 Q2	$39.3K	Buy	8,647 +2,906	+51%	+$11.5K	﹤0.01%	4394
2026 Q1	$23K	Sell	5,741 -41,958	-88%	-$205K	﹤0.01%	4553
2025 Q4	$333K	Buy	47,699 +21,231	+80%	+$119K	﹤0.01%	4078
2025 Q3	$123K	Sell	26,468 -3,469	-12%	-$16.2K	﹤0.01%	4552
2025 Q2	$163K	Buy	29,937 +29,905	+93,453%	+$160K	﹤0.01%	4387
2025 Q1	$177	Buy	+32	New	+$170	﹤0.01%	5119
2022 Q4	–	Sell	-296,422	Closed	-$2.94M	–	5371
2022 Q3	$2.94M	Buy	296,422 +94,012	+46%	+$930K	﹤0.01%	1489
2022 Q2	$1.99M	Buy	202,410 +194,264	+2,385%	+$1.91M	﹤0.01%	1852
2022 Q1	$80K	Buy	+8,146	New	+$80.4K	﹤0.01%	3895

Other funds holding TLSI

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Thompson Siegel & Walmsley Richmond, Virginia $5.37B AUM 3.99% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return

Provenance Wealth Advisors Fort Lauderdale, Florida $1.69B AUM 11.53% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Barclays's TLSI Position: Q3 2026 in Review

Barclays increased its TriSalus Life Sciences (TLSI) stake by 99% in Q3 2026, buying an estimated $40.7K and bringing the position to 17,243 shares worth $74.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4433.

Barclays first reported a position in TLSI in Q1 2022 and has held it in 10 quarters since. The position peaked at $2.94M in Q3 2022. 29 funds tracked by Wall St. Rank hold TLSI as of Q3 2026.

Barclays held 17,243 shares of TriSalus Life Sciences worth $74.3K as of Q3 2026.
Barclays bought 8,596 TriSalus Life Sciences shares in Q3 2026, an estimated $40.7K.
TriSalus Life Sciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4433 holding.
Barclays first reported a position in TriSalus Life Sciences in Q1 2022 and has held it in 10 quarters since.
Barclays's TriSalus Life Sciences position peaked at $2.94M in Q3 2022.
29 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.